📰 Multiple News
Page 241 - Multiple News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multiple. Real-time updates on events, politics, business and more.
May 11, 2023
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney... | May 11, 2023
May 11, 2023
Oryzon has reported Q123 results highlighting its near-term strategic priorities, including a favourable interim analysis of its lead asset study, the Phase IIb PORTICO study (vafidemstat, central nervous
May 11, 2023
LOS ANGELES, CA / ACCESSWIRE / May 11, 2023 / GBX International Group, Inc., (OTC:GBXI) an emerging leader in international economic development, is pleased to confirm its 2023 projected revenue growth
May 11, 2023
e-Sprinto, India’s fastest-growing electric two-wheeler brand has announced its latest partnership with...
May 11, 2023
Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from... | May 11, 2023
May 11, 2023
Company receives accolades from clients in UK and Brazil, and colleague awarded with Female Executive of the Year distinction Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end
May 11, 2023
MyJournals.org - Science - IJMS, Vol. 24, Pages 8603: Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells (International Journal of Molecular Sciences)
May 10, 2023
BASEL (dpa-AFX) - Evotec's Seattle-based subsidiary, Just - Evotec Biologics Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing
May 10, 2023
Bluegreen Points Home Resort: Cibola Vista Resort & Spa Peoria, Arizona THIS IS FOR THE PURCHASE OF THE TIMESHARE OWNERSHIP IN PERPETUITY. DETAILS: PLEASE NOTE THAT THIS IS AN EVEN YEAR OWNERSHIP Size | RealGeni.com
May 10, 2023
- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea - - Most Enrolled... | May 10, 2023